1947-00-8Relevant articles and documents
Targeting of phosphonoacetate to the liver: Synthesis of a phosphonoacetate-trilactoside conjugate
Bhat, Shridhar,Vaino, Andrew R.,Szarek, Walter A.
, p. 335 - 341 (2000)
As part of continuing studies on drug delivery to the human liver, a phosphonoacetate-trilactoside conjugate (12) has been synthesized in an overall yield of 23%. The shortness of the synthesis of this conjugate hinges upon a successful Michaelis-Arbuzov reaction of bromoacetamide 8 with tris-(trimethylsilyl) phosphite.
Structure-Activity Relationship of 18F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer
Dannoon, Shorouk,Ganguly, Tanushree,Cahaya, Hendry,Geruntho, Jonathan J.,Galliher, Matthew S.,Beyer, Sophia K.,Choy, Cindy J.,Hopkins, Mark R.,Regan, Melanie,Blecha, Joseph E.,Skultetyova, Lubica,Drake, Christopher R.,Jivan, Salma,Barinka, Cyril,Jones, Ella F.,Berkman, Clifford E.,Vanbrocklin, Henry F.
, p. 5684 - 5694 (2016)
A series of phosphoramidate-based prostate specific membrane antigen (PSMA) inhibitors of increasing lipophilicity were synthesized (4, 5, and 6), and their fluorine-18 analogs were evaluated for use as positron emission tomography (PET) imaging agents for prostate cancer. To gain insight into their modes of binding, they were also cocrystallized with the extracellular domain of PSMA. All analogs exhibited irreversible binding to PSMA with IC50 values ranging from 0.4 to 1.3 nM. In vitro assays showed binding and rapid internalization (80-95%, 2 h) of the radiolabeled ligands in PSMA(+) cells. In vivo distribution demonstrated significant uptake in CWR22Rv1 (PSMA(+)) tumor, with tumor to blood ratios of 25.6:1, 63.6:1, and 69.6:1 for [18F]4, [18F]5, and [18F]6, respectively, at 2 h postinjection. Installation of aminohexanoic acid (AH) linkers in the phosphoramidate scaffold improved their PSMA binding and inhibition and was critical for achieving suitable in vivo imaging properties, positioning [18F]5 and [18F]6 as favorable candidates for future prostate cancer imaging clinical trials.
Supramolecular hydrogel formed by glucoheptonamide of l-lysine: simple preparation and excellent hydrogelation ability
Suzuki, Masahiro,Owa, Sanae,Shirai, Hirofusa,Hanabusa, Kenji
, p. 7302 - 7308 (2007)
We describe the simple preparation of new l-lysine derivatives with a gluconic or glucoheptonic group, their hydrogelation properties, and the thermal and mechanical properties of the supramolecular hydrogels. The l-lysine derivatives with a gluconic group have no hydrogelation ability, while the l-lysine-glucoheptonamide derivatives functioned as hydrogelators. Their hydrogelation abilities increased with the decreasing length of the spacer between the l-lysine segment and the glucoheptonic group. The compound, which has no spacer, formed a supramolecular hydrogel at 0.05 wt % in pure water. The thermal stability and high mechanical strength of the supramolecular hydrogels based on this compound significantly depended on the aqueous solutions. Electron microscopy and FTIR studies demonstrated?that the hydrogelators created a three-dimensional network through hydrogen bonding and hydrophobic interactions in the supramolecular hydrogel. In addition, it was found that hydrophobic interactions played an important role in the thermal stability of the supramolecular hydrogel.
Method for synthesizing hexanediamine by taking caprolactam as raw material
-
, (2019/11/21)
The invention discloses a method for synthesizing hexanediamine by taking caprolactam as a raw material. The method comprises the following steps that (1) after the hexanediamine, alkali and water aremixed, heating reflux is conducted, and thus 6-amino-caproate is obtained; (2) the 6-amino-hexanoate obtained in the step (1) is introduced into an amino protecting group to protect an amino end group, then acid is added for neutralization to generate aminocaproic acid with the amino protecting group; (3) after a product obtained in the step (2) is dried, a dehydration catalyst for amide is added, a heating reaction is conducted in the presence of an ammonia source to convert a carboxylic acid group into a cyano group, and thus product nitrile is obtained; and (4) after the product nitrile obtained in the step (3) is extracted and purified, catalytic hydrogenation is conducted to generate corresponding amine, then the protecting group is removed, and thus a target product can be obtained.
CARBON MONOXIDE RELEASING NORBORNENONE COMPOUNDS
-
Page/Page column 56; 140; 141, (2017/09/27)
The present invention provides organic compounds which are capable of releasing carbon monoxide under physiological conditions or pH trigger, and to the use of such compounds for conditioning a cell, tissue or organ, for example, to protect against ischaemic injury during a transplant event.
